

Joint Event

30th International Conference on

Advanced Clinical Research and Clinical Trials

August 08-09, 2024

Webinar

20th World Congress on

Healthcare & Technologies

Gurpreet Singh, J Health Med Informat 2024, Volume 15

Global drug development: Current trends, challenges and opportunities

Gurpreet Singh

IQVIA, United Kingdom

The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over \$1 billion. Global Top Pharmaceutical Companies based on projected R&D spending in 2026 are Roche, Johnson & Johnson, Merck & Co, Pfizer and Novartis. The global CRO services market in terms of revenue was estimated to be worth \$76.6 billion in 2023 and is poised to reach \$127.3 billion by 2028.

Global Drug Development Trends

- Increased Focus on Quality, Compliance and Quality Management System
- Requirements of Audit and Inspection readiness
- Process Enhancements, Changes, Improvements
- Further adoption of Technology and Tools, Database migrations
- Focus on Data Analytics and Trends
- Organizational Culture Enhancement –Focus on People Development, Training and Retention
- Change Management – Mergers / Acquisitions and Integrations

Global Drug Development Challenges and Opportunities

- Requirement of skilled resources
- Retention of Talent
- People Development Needs
- Standard Operating Procedures
- Better quality and compliance
- Need for better productivity
- Adoption of Technology
- Reduce cost per transaction
- Improve Efficiency

Joint Event

30th International Conference on

Advanced Clinical Research and Clinical Trials

August 08-09, 2024

Webinar

20th World Congress on

Healthcare & Technologies

What will audience learn from your presentation?

- Understanding of the Global Drug Development Industry. The current trends, challenges and opportunities
- Four important pillars of Drug Development – People, Process, Technology and Partnerships
- Digital Transformation in Drug Development
- Top 10 Trends in Drug Development like Personalized medicine, Orphan drugs for rare diseases and New clinical trial models (Decentralized Clinical Trials)

Biography

Gurpreet Singh is currently the Vice President, Managing Director Integrated Safety at IQVIA. He is based in UK and has a total of 18 years' experience in Pharma Industry of which 16+ years have been in Global Drug Development. During these years he has had the opportunity to work with some top Global companies like Cognizant, Tata Consultancy, Novartis and Parexel. At Novartis he was the Global Head of PV Operations managing all Global PV activities. At Parexel he was the Senior Director PV Operations responsible for managing PV projects of top Global Pharma and Biotech companies.

Received: May 31, 2024; **Accepted:** June 03, 2024; **Published:** August 24, 2024
